Abstract: PO0443
Biomarkers of Immune Activation and ESKD: Results from AASK
Session Information
- CKD Epidemiology, Biomarkers, Predictors
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Chen, Teresa K., Johns Hopkins University, Baltimore, Maryland, United States
- Estrella, Michelle M., University of California San Francisco, San Francisco, California, United States
- Appel, Lawrence J., Johns Hopkins University, Baltimore, Maryland, United States
- Coresh, Josef, Johns Hopkins University, Baltimore, Maryland, United States
- Luo, Shengyuan, Johns Hopkins University, Baltimore, Maryland, United States
- Reiser, Jochen, Rush University, Chicago, Illinois, United States
- Obeid, Wassim, Johns Hopkins University, Baltimore, Maryland, United States
- Parikh, Chirag R., Johns Hopkins University, Baltimore, Maryland, United States
- Grams, Morgan, Johns Hopkins University, Baltimore, Maryland, United States
Background
Immune activation is fundamental to the pathogenesis of many kidney diseases, and innate immune molecules such as soluble urokinase-type plasminogen activator receptor (suPAR) have been linked to incidence and progression of CKD. Whether other biomarkers of immune activation are associated with ESKD in African Americans with non-diabetic kidney disease is unclear.
Methods
Utilizing baseline serum samples from AASK, we measured 4 biomarkers of immune activation (soluble tumor necrosis factor receptors 1 and 2 [sTNFR1, sTNFR2], tumor necrosis factor alpha [TNF-α], interferon gamma [IFN-γ]) and examined their associations with ESKD and all-cause mortality. Covariates included age, sex, systolic BP, BMI, smoking, baseline GFR and urine PCR. We also considered interactive effects of each biomarker with APOL1 risk status.
Results
Among 500 participants with available samples, mean GFR was 44.7 ml/min/1.73 m2 and median urine PCR was 0.09 g/g at baseline. Over a median follow-up 9.6 yrs, there were 161 (32%) ESKD and 113 (23%) death events. In fully adjusted models, each two-fold higher baseline level of sTNFR1, sTNFR2, and TNF-α was associated with 3.66, 2.29, and 1.35-fold greater risks of ESKD, respectively (Table). In comparison, the association between suPAR and ESKD was 1.39 (95% CI: 1.04, 1.86). These three biomarkers were also significantly associated with death (up to 2.2-fold higher risks per 2-fold higher baseline level; p≤0.01). IFN-γ was not associated with either outcome. None of the biomarkers modified APOL1-associated risks for ESKD (p-interaction>0.05). The C-statistic for the fully adjusted clinical model in predicting ESKD was excellent at 0.849 (95% CI: 0.820, 0.878). Adding sTNFR1, the biomarker with the strongest association, to the clinical model led to a small but statistically significant improvement in the C-statistic at 0.860 (95% CI: 0.833, 0.887; difference of 0.011; 95% CI: 0.001, 0.021).
Conclusion
Among African Americans with CKD attributed to hypertension, baseline levels of sTNFR1, sTNFR2, and TNF-α but not IFN-γ were associated with ESKD and mortality.
Funding
- NIDDK Support